Skip to main content
ELTX
NASDAQ Life Sciences

Elicio Q3 Loss Narrows to $8.0M; Cash Runway Extended to Q2 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.405
Mkt Cap
$37.928M
52W Low
$1.4
52W High
$16
52W Position info
0.4% above low
Off High info
91% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ELTX is trading near its 52-week low of $1.4 (0.4% above the low).

Summary

Elicio reported a narrower Q3 2026 net loss of $8.0 million and $30.9 million in cash, extending runway into Q2 2027, while new AMPLIFY-7P subgroup data support a targeted Phase 3 strategy in adjuvant pancreatic cancer.


Key Events · Earnings and Guidance · ELTX

  • Q3 Loss Narrows to $8.0M

    Net loss for Q3 2026 was $8.0 million, or $0.30 per share, versus $10.1 million, or $0.60 per share, in Q3 2025. R&D fell to $4.9 million from $5.0 million, while G&A rose to $3.6 million from $3.0 million.

  • Cash Runway Extended to Q2 2027

    Cash and cash equivalents stood at $30.9 million as of September 30, 2026, which the company expects to support operations into the second quarter of 2027.

  • New AMPLIFY-7P Subgroup Analyses

    Pre-specified analyses showed a 49% reduction in risk of recurrence or death in ctDNA-negative patients, 43% in ctDNA-positive patients and 41% in patients without prior radiation; a multivariable analysis estimated HR 0.47 (p=0.0086). The trial still missed its primary DFS endpoint in the intent-to-treat population.

  • Phase 1 Combination Study Targeted Q4 2026

    Elicio is targeting a Q4 2026 start for a Phase 1 study of camupepimut with daraxonrasib, with or without nivolumab, in metastatic KRAS-mutated PDAC.


Analysis · ELTX · Life Sciences

Elicio's Q3 net loss narrowed to $8.0 million from $10.1 million a year ago, and with $30.9 million in cash the company now funds operations into the second quarter of 2027—roughly a quarter longer than the prior Q1 2027 guidance. That buys time, but going-concern doubt previously disclosed in the 10-K still hangs over the story, and the company must keep funding a Phase 3 adjuvant PDAC plan after the AMPLIFY-7P trial missed its primary endpoint on October 23. New subgroup analyses—a 49% reduction in recurrence or death risk in ctDNA-negative patients and a 43% reduction in ctDNA-positive patients—underpin a narrower, biomarker-targeted Phase 3 strategy rather than a broad one. A Phase 1 combination study with daraxonrasib is targeted for Q4 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ELTX was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.9M. The 52-week trading range was $1.40 to $16.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELTX - Latest Insights

ELTX
Nov 05, 2026, 4:14 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.41
Real-time Price: $1.38 info
Change: -$0.025 (-2%) info
Market Cap: $42.461M info
ELTX
Oct 23, 2026, 9:00 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.78
Real-time Price: $1.38 info
Change: -$0.400 (-22%) info
Market Cap: $42.461M info
ELTX
Aug 13, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.10
Real-time Price: $1.38 info
Change: -$1.72 (-56%) info
Market Cap: $42.461M info
ELTX
Jul 06, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.26
Real-time Price: $1.38 info
Change: -$1.88 (-58%) info
Market Cap: $42.461M info
ELTX
Jul 02, 2026, 6:20 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.16
Real-time Price: $1.38 info
Change: -$2.78 (-67%) info
Market Cap: $42.461M info